Greenwich LifeSciences Provides Year End Update
Greenwich LifeSciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have... | December 29, 2022
Source: marketscreener.com